Zaheer Zahid, Khan Firoz A Kalam, Sangshetti Jaiprakash N, Patil Rajendra H
Department of Pharmaceutical Chemistry, Y. B. Chavan College of Pharmacy, Dr. Rafiq Zakaria Campus, Aurangabad 431 001(MS), India.
Department of Biotechnology, Savitribai Phule Pune University, Pune 411007, (MS), India.
EXCLI J. 2015 Aug 10;14:935-47. doi: 10.17179/excli2015-244. eCollection 2015.
Bis-(4-hydroxycoumarin-3-yl) methane derivatives 3(a-l) were synthesized from 4-hydroxycoumarin and substituted aromatic aldehydes using succinimide-N-sulfonic acid as catalyst and evaluated for their in vitro antileishmanial activity against promastigotes form of Leishmania donovani. Compounds 3a (IC50= 155 μg/mL), 3g (IC50= 157.5 μg/mL) and 3l (IC50= 150 μg/mL) were shown significant antileishmanial activity when compared with standard sodium stibogluconate (IC50= 490 μg/mL). Also, synthesized compounds 3(a-l) did not show cytotoxicity against HeLa cell line upto tested concentrations. Further, molecular docking study against Adenine phosphoribosyltransferase of Leishmania donovani showed good binding interactions. ADME properties were analyzed and showed good oral drug candidate like properties. The synthesized compounds were also shown good drug likeness and drug score values when compared with drugs currently used in therapy. The present study has helped us in identifying a new lead that could be exploited as a potential antileishmanial agent.
以琥珀酰亚胺 - N - 磺酸为催化剂,由4 - 羟基香豆素与取代芳香醛合成了双 -(4 - 羟基香豆素 - 3 - 基)甲烷衍生物3(a - l),并对其针对杜氏利什曼原虫前鞭毛体形式的体外抗利什曼活性进行了评估。与标准药物葡萄糖酸锑钠(IC50 = 490 μg/mL)相比,化合物3a(IC50 = 155 μg/mL)、3g(IC50 = 157.5 μg/mL)和3l(IC50 = 150 μg/mL)表现出显著的抗利什曼活性。此外,在所测试的浓度范围内,合成的化合物3(a - l)对HeLa细胞系未显示出细胞毒性。进一步的研究表明,针对杜氏利什曼原虫腺嘌呤磷酸核糖转移酶的分子对接显示出良好的结合相互作用。对药物的吸收、分布、代谢和排泄(ADME)特性进行了分析,结果表明其具有良好的口服药物候选特性。与目前治疗中使用的药物相比,合成的化合物还显示出良好的类药性质和药物评分值。本研究有助于我们确定一种新的先导化合物,其可作为潜在的抗利什曼病药物加以开发利用。